Related Experiment Video
Updated: Jun 15, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches
Chad A Caraway1, Hallie Gaitsch1,2, Elizabeth E Wicks1,3
1Hunterian Neurosurgical Research Laboratory, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Abstract:
Translation of novel therapies for brain cancer into clinical practice is of the utmost importance as primary brain tumors are responsible for more than 200,000 deaths worldwide each year. While many research efforts have been aimed at improving survival rates over the years, prognosis for patients with glioblastoma and other primary brain tumors remains poor. Safely delivering chemotherapeutic drugs and other anti-cancer compounds across the blood-brain barrier and directly to tumor cells is perhaps the greatest challenge in treating brain cancer. Polymeric nanoparticles (NPs) are powerful, highly tunable carrier systems that may be able to overcome those obstacles. Several studies have shown appropriately-constructed polymeric NPs cross the blood-brain barrier, increase drug bioavailability, reduce systemic toxicity, and selectively target central nervous system cancer cells. While no studies relating to their use in treating brain cancer are in clinical trials, there is mounting preclinical evidence that polymeric NPs could be beneficial for brain tumor therapy. This review includes a variety of polymeric NPs and how their associated composition, surface modifications, and method of delivery impact their capacity to improve brain tumor therapy.
Insights
Polymeric nanoparticles offer a promising strategy for brain cancer treatment by overcoming the blood-brain barrier. These novel carriers enhance drug delivery and targeting for improved glioblastoma therapy.
Area of Science:
- Nanomedicine
- Oncology
- Biotechnology
Background:
- Primary brain tumors, including glioblastoma, result in over 200,000 deaths annually, with poor patient prognosis.
- Current treatments face significant challenges in delivering therapeutic agents across the blood-brain barrier (BBB) to target tumor cells effectively.
- Despite extensive research, improving survival rates for primary brain cancer remains a critical unmet medical need.
Purpose of the Study:
- To review the potential of polymeric nanoparticles (NPs) as advanced drug delivery systems for brain cancer therapy.
- To explore how NP composition, surface modifications, and delivery methods influence their efficacy in overcoming the BBB and targeting CNS tumors.
- To highlight the preclinical evidence supporting the use of polymeric NPs in improving brain tumor treatment.
Main Methods:
- Review of existing scientific literature on polymeric nanoparticles and their application in brain cancer research.
- Analysis of studies demonstrating the ability of engineered polymeric NPs to cross the blood-brain barrier.
- Evaluation of research on NP-mediated drug delivery, targeting specificity, and systemic toxicity reduction for CNS cancers.
Main Results:
- Polymeric nanoparticles demonstrate the capacity to traverse the blood-brain barrier.
- Engineered NPs can enhance the bioavailability of chemotherapeutic drugs and reduce systemic toxicity.
- Preclinical studies indicate selective targeting of central nervous system cancer cells by polymeric NPs.
Conclusions:
- Polymeric nanoparticles represent a highly tunable and promising platform for enhancing brain tumor therapy.
- Further development and clinical translation of polymeric NP-based strategies are warranted to improve outcomes for brain cancer patients.
- Optimizing NP design, including composition and surface functionalization, is crucial for maximizing therapeutic benefits in brain cancer treatment.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...